Oncology Prior Authorization Automation: Accelerating Cancer Care

The Unique Complexity of Oncology Prior Authorization

Oncology prior authorization is among the most intricate in healthcare, characterized by high-cost biologics, complex infusion regimens, radiation oncology procedures, and frequent treatment modifications. Each patient's journey often involves dozens of PA events across diagnosis, staging, treatment initiation, supportive care, and surveillance, directly impacting diagnosis-to-treatment intervals critical for patient outcomes.

Key Prior Authorization Triggers in Oncology

• J-code chemotherapy and biologic infusions (e.g., immunotherapies, targeted therapies)
• Advanced imaging for staging and surveillance (e.g., PET/CT, tumor-specific molecular imaging)
• Radiation oncology procedures (e.g., IMRT, SBRT, proton-beam therapy CPT ranges)
• Genetic and molecular testing (e.g., NGS panels, hereditary cancer panels)
• Specialty oral oncolytics and supportive care medications (e.g., growth factors, antiemetics)

Critical Documentation and Medical Necessity Frameworks

Oncology PAs rely heavily on the NCCN Clinical Practice Guidelines (src: nccn-guidelines) and the NCCN Drugs & Biologics Compendium (src: nccn-compendium) for medical necessity. Payers consistently require detailed documentation including pathology reports, tumor staging (AJCC TNM), molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, and performance status (ECOG or Karnofsky score).

Common Challenges Leading to Oncology PA Denials

• Off-label use without sufficient NCCN Compendium support (src: nccn-compendium)
• Step therapy requirements for biologics or oral targeted therapies
• Documentation gaps (e.g., missing molecular marker results, prior-line response)
• Site-of-service mismatches (e.g., HOPD vs. home infusion)
• NCD/LCD non-coverage for Medicare Advantage plans (src: cms-ncds)
• Experimental indications lacking payer policy or compendium acceptance

Klivira's Approach to Oncology Prior Authorization Automation

Klivira's platform is purpose-built to navigate the dual benefit pathways of oncology drugs – medical benefit (IV infusions via X12 278 or payer portals) and pharmacy benefit (oral oncolytics via PBMs and ePA partners like CoverMyMeds). We address the start-of-treatment urgency and frequent regimen changes by providing a comprehensive, automated solution that streamlines submissions and appeals.

Klivira's Oncology-Specific Automation Capabilities

• NCCN-compendium-aware policy logic that surfaces required documentation at the point of order entry
• Regimen-level PA workflow that bundles related components for multi-drug cancer regimens
• Intelligent medical-vs-pharmacy benefit routing for seamless processing of all oncology drugs
• Concurrent PA tracking for the dozens of PA events per patient over a treatment course
• Integrated peer-to-peer scheduling to facilitate oncologist-payer reviews for clinical necessity denials